2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Conditions
Carcinoma, Non-Small-Cell Lung
465
Melanoma
300
Squamous Cell Carcinoma of Head and Neck
234
Parkinson Disease 4, Autosomal Dominant Lewy Body
189
Neoplasms
186
Triple Negative Breast Neoplasms
163
Breast Neoplasms
162
Neoplasm Metastasis
158
Lung Neoplasms
148
Colorectal Neoplasms
143
Carcinoma, Renal Cell
132
Head and Neck Neoplasms
123
Stomach Neoplasms
105
Ovarian Neoplasms
101
Carcinoma, Transitional Cell
93
Urinary Bladder Neoplasms
82
Pancreatic Neoplasms
82
Endometrial Neoplasms
74
Carcinoma, Hepatocellular
74
Uterine Cervical Neoplasms
63
Esophageal Neoplasms
57
Recurrence
52
Prostatic Neoplasms
49
Sarcoma
43
Carcinoma
43
Glioblastoma
40
Small Cell Lung Carcinoma
39
Carcinoma, Squamous Cell
39
Hodgkin Disease
36
Cholangiocarcinoma
36
Interventions
pralsetinib
1
pembrolizumab
1
Pemetrexed
1
Paclitaxel
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Bronchial Diseases
×
pembrolizumab
×
Clear all
NCT04222972
2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3
Terminated
223 enrolled
18 charts